Want to see HK:1541 full AI Analyst Report?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Ratios
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Ratios
HK:1541's free cash flow for Q2 2026 was $-161.60M. For the 2026 fiscal year, HK:1541's free cash flow was decreased by $-1.20M and operating cash flow was $-160.39M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.83 | 4.04 | 5.92 | 12.60 | 0.28 |
| Quick Ratio | 3.83 | 3.93 | 5.92 | 12.42 | 0.28 |
| Cash Ratio | 2.47 | 2.23 | 2.65 | 12.28 | 0.27 |
| Solvency Ratio | -0.64 | -1.25 | -2.83 | -6.34 | -0.29 |
| Operating Cash Flow Ratio | -0.71 | -0.60 | -3.17 | -4.61 | -0.08 |
| Short-Term Operating Cash Flow Coverage | -1.04 | -1.27 | -6.13 | 0.00 | 0.00 |
| Net Current Asset Value | $ 748.76M | $ 624.25M | $ 560.40M | $ 591.11M | $ -1.79B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.21 | 0.15 | 0.09 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.29 | 0.20 | 0.10 | 0.02 | -0.01 |
| Debt-to-Capital Ratio | 0.22 | 0.17 | 0.09 | 0.02 | -0.01 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.39 | 1.36 | 1.17 | 1.08 | -0.56 |
| Debt Service Coverage Ratio | -1.05 | -2.83 | -5.78 | -488.55 | -806.83 |
| Interest Coverage Ratio | -42.05 | -89.31 | -239.29 | -463.09 | -236.21 |
| Debt to Market Cap | 0.10 | 0.06 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.57 | 0.37 | 0.21 | 0.04 | 0.05 |
| Net Debt to EBITDA | 2.22 | 1.15 | 0.65 | 1.61 | 0.90 |
| Profitability Margins | |||||
| Gross Profit Margin | 89.81% | 100.00% | 1993.52% | 100.00% | 100.00% |
| EBIT Margin | -144.55% | -415.44% | -97910.62% | -7066.91% | -5301.69% |
| EBITDA Margin | -135.08% | -398.70% | -92060.10% | -6757.29% | -5206.27% |
| Operating Profit Margin | -144.55% | -415.44% | -94474.87% | -6405.13% | -1524.23% |
| Pretax Profit Margin | -142.10% | -426.96% | -98305.44% | -7080.74% | -5308.15% |
| Net Profit Margin | -141.66% | -425.97% | -98305.44% | -7080.74% | -5308.15% |
| Continuous Operations Profit Margin | -142.12% | -426.96% | -98305.44% | -7080.74% | -5308.15% |
| Net Income Per EBT | 99.69% | 99.77% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 98.31% | 102.77% | 104.05% | 110.55% | 348.25% |
| Return on Assets (ROA) | -19.38% | -34.26% | -43.39% | -47.96% | -82.09% |
| Return on Equity (ROE) | -26.89% | -46.52% | -50.71% | -51.70% | 45.85% |
| Return on Capital Employed (ROCE) | -26.39% | -43.55% | -48.07% | -46.24% | 13.28% |
| Return on Invested Capital (ROIC) | -21.33% | -37.81% | -44.31% | -45.91% | 13.32% |
| Return on Tangible Assets | -19.38% | -34.26% | -47.50% | -53.01% | -90.64% |
| Earnings Yield | -9.86% | -17.28% | -3.87% | -6.26% | -12.35% |
| Efficiency Ratios | |||||
| Receivables Turnover | 10.62 | 402.98 | 9.90 | 86.21 | 406.12 |
| Payables Turnover | 1.12 | 0.00 | -0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 4.48 | 1.55 | 0.00 | 0.03 | 0.08 |
| Asset Turnover | 0.14 | 0.08 | 0.00 | 0.01 | 0.02 |
| Working Capital Turnover Ratio | 0.21 | 0.12 | 0.00 | -0.01 | 0.00 |
| Cash Conversion Cycle | -291.93 | 0.91 | 102061.61 | 4.23 | 0.90 |
| Days of Sales Outstanding | 34.38 | 0.91 | 36.88 | 4.23 | 0.90 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 326.31 | 0.00 | -102024.73 | 0.00 | 0.00 |
| Operating Cycle | 34.38 | 0.91 | 36.88 | 4.23 | 0.90 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.47 | -0.34 | -1.02 | -0.64 | -0.51 |
| Free Cash Flow Per Share | -0.48 | -0.37 | -1.02 | -0.70 | -0.85 |
| Dividend Paid and CapEx Coverage Ratio | -153.12 | -12.31 | -136.59 | -10.28 | -1.52 |
| Capital Expenditure Coverage Ratio | -153.12 | -12.31 | -136.59 | -10.28 | -1.52 |
| Operating Cash Flow Coverage Ratio | -0.86 | -0.94 | -4.92 | -16.33 | -10.28 |
| Operating Cash Flow to Sales Ratio | -1.30 | -1.73 | -952.21 | -41.95 | -13.80 |
| Free Cash Flow Yield | -9.13% | -7.57% | -3.78% | -4.07% | -5.32% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.27 | -5.79 | -25.83 | -15.97 | -8.10 |
| Price-to-Sales (P/S) Ratio | 14.37 | 24.65 | 25394.57 | 1130.62 | 429.71 |
| Price-to-Book (P/B) Ratio | 2.73 | 2.69 | 13.10 | 8.26 | -3.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -10.96 | -13.20 | -26.48 | -24.56 | -18.79 |
| Price-to-Operating Cash Flow Ratio | -11.03 | -14.28 | -26.67 | -26.95 | -31.14 |
| Price-to-Earnings Growth (PEG) Ratio | 0.26 | 0.29 | 9.30 | 0.36 | 0.00 |
| Enterprise Value Multiple | -8.41 | -5.03 | -26.93 | -15.12 | -7.35 |
| Enterprise Value | 1.71B | 1.49B | 9.57B | 5.81B | 5.28B |
| EV to EBITDA | -8.41 | -5.03 | -26.93 | -15.12 | -7.35 |
| EV to Sales | 11.36 | 20.05 | 24792.99 | 1021.55 | 382.65 |
| EV to Free Cash Flow | -8.66 | -10.74 | -25.85 | -22.19 | -16.73 |
| EV to Operating Cash Flow | -8.72 | -11.61 | -26.04 | -24.35 | -27.73 |
| Tangible Book Value Per Share | 1.92 | 1.80 | 1.86 | 1.87 | -4.51 |
| Shareholders’ Equity Per Share | 1.92 | 1.80 | 2.07 | 2.09 | -4.28 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.36 | 0.20 | 0.00 | 0.02 | 0.04 |
| Net Income Per Share | -0.52 | -0.84 | -1.05 | -1.08 | -1.96 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.98 | 1.03 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 2.09 | 4.35 | 756.33 | 48.74 | 12.74 |
| SG&A to Revenue | 0.25 | 0.87 | 208.35 | 16.31 | 3.50 |
| Stock-Based Compensation to Revenue | 0.10 | 0.46 | 185.60 | 18.25 | 2.46 |
| Income Quality | 0.92 | 0.40 | 0.97 | 0.59 | 0.26 |
Currency in CNY
